Will Editas in-vivo sickle cell therapy enter clinical trials by October 2025? | Binary | | | 2 months ago | |
Will Editas' in vivo gene therapy be declared the lead program among CRISPR companies by mid-2025? | Binary | | | 2 months ago | |
What will be the outcome of Editas Medicine's $238 million biobucks agreement by end of 2025? | Categorical | | | 2 months ago | |
Will Editas secure a partner for ex-vivo sickle cell treatment by mid-2025? | Binary | | | 2 months ago | |
Will Editas Medicine achieve proof-of-concept for in vivo sickle cell treatment by end of 2024? | Binary | | | 2 months ago | |
Will Editas Medicine announce a partnership for its ex vivo sickle cell program by Q1 2025? | Binary | | | 2 months ago | |
What will be Editas Medicine's next major milestone in in vivo gene therapy by end of 2024? | Categorical | | | 2 months ago | |
Which CRISPR company will first declare in vivo sickle cell treatment as lead program by end of 2024? | Categorical | | | 2 months ago | |
Which company will partner with Editas for ex-vivo sickle cell treatment by mid-2025? | Categorical | | | 2 months ago | |
Who will be the major competitor to Editas in-vivo sickle cell therapy by end of 2025? | Categorical | | | 2 months ago | |
Will Editas achieve proof-of-concept for in-vivo sickle cell therapy by end of 2025? | Binary | | | 2 months ago | |
What will be the outcome of Editas in-vivo sickle cell therapy trials by end of 2025? | Categorical | | | 2 months ago | |
